Skip to main content
HAEMONETICS CORP logo

HAEMONETICS CORP — Investor Relations & Filings

Ticker · HAE ISIN · US4050241003 LEI · 549300ZEL6TXZS6F5F95 US Manufacturing
Open in API
Filings indexed 1,280 across all filing types
Latest filing 2026-06-09 Annual Report
Country US United States of America
Listing US HAE

About HAEMONETICS CORP

https://www.haemonetics.com

Haemonetics Corporation is a global medical technology company that provides a suite of innovative solutions designed to improve the quality, effectiveness, and efficiency of healthcare. The company's portfolio serves customers across hospitals, blood centers, and plasma collection centers. Its business focuses on three key areas: Hospital, Plasma, and Blood Center. The Hospital division offers products for hemostasis management, such as TEG® systems; cell salvage systems, including Cell Saver®; and vascular closure devices. For the plasma and blood collection markets, Haemonetics provides automated collection technology, software, and services to manage the blood supply chain from donor to patient. The company's offerings encompass a range of devices, disposables, and information management solutions aimed at advancing patient care.

Recent filings

Filing Released Lang Actions
ARS
Annual Report
2026-06-09 English
DEFA14A
Proxy Solicitation & Information Statement
2026-06-09 English
DEF 14A
Proxy Solicitation & Information Statement
2026-06-09 English
8-K
Regulatory Filings Classification · 86% confidence The document is a Form 8-K “Current Report” filed with the SEC under Section 13/15(d), containing a Regulation FD disclosure of a segment reporting structural change and a press release exhibit. There are no full financial statements, earnings figures, or dividend details, and it is not an annual or interim report, proxy, or M&A filing. It is a general regulatory filing announcement, so it is best classified under Regulatory Filings (RNS).
2026-06-05 English
SD
Regulatory Filings Classification · 91% confidence The document is an SEC Form SD (“Specialized Disclosure Report”) filed under Rule 13p-1 relating to conflict minerals. It is a compliance filing with the Securities and Exchange Commission rather than a full annual or interim financial report, earnings release, governance policy, or sustainability report. It does not contain substantive financial statements but rather discloses regulatory compliance information. Thus, it best fits into the fallback category of Regulatory Filings (RNS).
2026-05-28 English
10-K
Annual Report FY 2026
2026-05-20 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.